TY - JOUR
T1 - Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
AU - Major, Catherine Kendall
AU - Kantarjian, Hagop
AU - Sasaki, Koji
AU - Borthakur, Gautam
AU - Kadia, Tapan
AU - Pemmaraju, Naveen
AU - DiNardo, Courtney
AU - Short, Nicholas J.
AU - Daver, Naval
AU - Jabbour, Elias
AU - Champlin, Richard
AU - Garcia-Manero, Guillermo
AU - Konopleva, Marina
AU - Andreeff, Michael
AU - Kornblau, Steven
AU - Wierda, William
AU - Pierce, Sherry
AU - Ravandi, Farhad
AU - Cortes, Jorge
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020
Y1 - 2020
N2 - Acute myeloid leukemia (AML) carries poor survival and high recurrence rate. We conducted a retrospective analysis of AML patients (N = 453) treated with chemotherapy only or chemotherapy + hematopoietic cell transplant (HCT) who maintained their first complete remission (CR) for ≥3 years. Prior comorbidities, new comorbidities, secondary malignancies, late relapse, and causes of death (COD) were documented. New comorbidities for chemotherapy only patients (n = 304) included renal disease (10%), and osteopenia/osteoporosis (38%) for HCT patients (n = 149). Incidence of hypertension was similar in the chemotherapy only cohort and chemotherapy + HCT cohort (14% vs 17%). Secondary malignancies occurred in 13%, commonly skin, prostate and breast cancers. Common COD included: secondary malignancy (4%), HCT complications (3%), and late relapses (5%). Overall, 12% had a late relapse. Median overall survival for chemotherapy only and HCT was 10.7 and 12.7 years, respectively. Long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.
AB - Acute myeloid leukemia (AML) carries poor survival and high recurrence rate. We conducted a retrospective analysis of AML patients (N = 453) treated with chemotherapy only or chemotherapy + hematopoietic cell transplant (HCT) who maintained their first complete remission (CR) for ≥3 years. Prior comorbidities, new comorbidities, secondary malignancies, late relapse, and causes of death (COD) were documented. New comorbidities for chemotherapy only patients (n = 304) included renal disease (10%), and osteopenia/osteoporosis (38%) for HCT patients (n = 149). Incidence of hypertension was similar in the chemotherapy only cohort and chemotherapy + HCT cohort (14% vs 17%). Secondary malignancies occurred in 13%, commonly skin, prostate and breast cancers. Common COD included: secondary malignancy (4%), HCT complications (3%), and late relapses (5%). Overall, 12% had a late relapse. Median overall survival for chemotherapy only and HCT was 10.7 and 12.7 years, respectively. Long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.
KW - Acute myeloid leukemia
KW - comorbidities
KW - remission
KW - survivorship
UR - http://www.scopus.com/inward/record.url?scp=85089068449&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1802450
DO - 10.1080/10428194.2020.1802450
M3 - Article
C2 - 32755333
AN - SCOPUS:85089068449
SN - 1042-8194
VL - 61
SP - 3120
EP - 3127
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 13
ER -